Open AccessNivolumab infusion reaction manifesting as plantar erythema and pulmonary infiltrate in a lung cancer patient
Author(s) -
Ogawara Daiki,
Soda Hiroshi,
Ikehara Susumu,
Sumiyoshi Makoto,
Iwasaki Keisuke,
Okuno Daisuke,
Dohtsu Yosuke,
Taniguchi Hirokazu,
Harada Tatsuhiko,
Fukuda Yuichi,
Mukae Hiroshi
Publication year - 2017
Publication title -
thoracic cancer
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.823
H-Index - 28
eISSN - 1759-7714
pISSN - 1759-7706
DOI - 10.1111/1759-7714.12494
Subject(s) - nivolumab , medicine , lung cancer , erythema , lung , monoclonal antibody , etiology , adverse effect , antibody , pathology , cancer , immunotherapy , dermatology , immunology
Infusion reaction is an adverse event of therapeutic monoclonal antibodies. Nivolumab, an anti‐programmed death‐1 antibody, directly activates T cells, which could probably interact with endothelial cells. The etiology of infusion reaction induced by nivolumab may differ from that of other antibodies; however, the detailed clinical features are unknown. We report a case of lung cancer treated with nivolumab, in which the infusion reaction manifested as plantar erythema, followed by a transient local pulmonary infiltrate around the tumor. Physicians should be aware that an infusion reaction induced by anti‐programmed death‐1 antibodies could appear as local cutaneous and pulmonary adverse events.